Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.

Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Tachihara M, Nakatani T, Harada T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Yoshizumi Y, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Mamesaya N, Misumi T, Matsutani N, Seki N

Open source

DOI
10.1016/j.jtocrr.2026.100972
Published
2026 Apr
Container
JTO clinical and research reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2026.100972,
  title = {Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.},
  author = {Ishihara M and Kawamura T and Namba Y and Takeyasu Y and Hasegawa Y and Sato Y and Negi Y and Oba T and Sumi T and Hirata H and Funabashi H and Oya Y and Kikuchi H and Tachihara M and Nakatani T and Harada T and Tanimura K and Nakagawa T and Takeda N and Asami T and Honjo O and Nagashima H and Yamaura T and Hata N and Kitazono M and Nishioka N and Tamiya A and Sakamori Y and Shigaki R and Kaira K and Honda R and Matsui T and Suzuki E and Ito K and Otsuka K and Yoshizumi Y and Murakami Y and Matsuno K and Inoue S and Kisohara A and Kusumoto S and Aoshima H and Kakizaki Y and Kubo A and Hata A and Ishikawa N and Hamai K and Kanaji N and Mamesaya N and Misumi T and Matsutani N and Seki N},
  year = {2026},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2026.100972},
  url = {https://doi.org/10.1016/j.jtocrr.2026.100972}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
AU  - Ishihara M
AU  - Kawamura T
AU  - Namba Y
AU  - Takeyasu Y
AU  - Hasegawa Y
AU  - Sato Y
AU  - Negi Y
AU  - Oba T
AU  - Sumi T
AU  - Hirata H
AU  - Funabashi H
AU  - Oya Y
AU  - Kikuchi H
AU  - Tachihara M
AU  - Nakatani T
AU  - Harada T
AU  - Tanimura K
AU  - Nakagawa T
AU  - Takeda N
AU  - Asami T
AU  - Honjo O
AU  - Nagashima H
AU  - Yamaura T
AU  - Hata N
AU  - Kitazono M
AU  - Nishioka N
AU  - Tamiya A
AU  - Sakamori Y
AU  - Shigaki R
AU  - Kaira K
AU  - Honda R
AU  - Matsui T
AU  - Suzuki E
AU  - Ito K
AU  - Otsuka K
AU  - Yoshizumi Y
AU  - Murakami Y
AU  - Matsuno K
AU  - Inoue S
AU  - Kisohara A
AU  - Kusumoto S
AU  - Aoshima H
AU  - Kakizaki Y
AU  - Kubo A
AU  - Hata A
AU  - Ishikawa N
AU  - Hamai K
AU  - Kanaji N
AU  - Mamesaya N
AU  - Misumi T
AU  - Matsutani N
AU  - Seki N
PY  - 2026
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2026.100972
UR  - https://doi.org/10.1016/j.jtocrr.2026.100972
ER  -

APA

M, I., T, K., Y, N., Y, T., Y, H., Y, S., Y, N., T, O., T, S., H, H., H, F., Y, O., H, K., M, T., T, N., T, H., K, T., T, N., N, T., T, A., O, H., H, N., T, Y., N, H., M, K., N, N., A, T., Y, S., R, S., K, K., R, H., T, M., E, S., K, I., K, O., Y, Y., Y, M., K, M., S, I., A, K., S, K., H, A., Y, K., A, K., A, H., N, I., K, H., N, K., N, M., T, M., N, M., & N, S. (2026). Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2026.100972

Source records